Uzbekistan, Tashkent, Aug. 5 / Trend D. Azizov /
Uzbekistan in 2012-2013 will direct $290.5 million to the development of the pharmaceutical industry, the Uzbek pharmaceutical industry state joint-stock company said on Friday.
In total, until 2014 it is planned to implement 39 investment projects for production of 30 new drugs of generic number for the prevention and treatment of socially significant and socially dangerous diseases. These products are in high demand and are imported into the country mainly on import contracts.
Before late 2012 Salubris Vita joint venture (Tashkent region) plans to start operating the production of drugs that normalize the intestinal microflora worth $21 million. JV Al-Bi Pharma (Tashkent) will establish production of vitamin preparations worth $8 million, Nicka Pharm (Tashkent) will start producing cardiac drugs ($ 5.3 million).
In 2013, the industry plans to start the project for the production of antibiotic substances cephalosporin worth $37 million and antiviral drugs ($15 million) on the basis of the Navoi free industrial economic zone, as well as plasma substitutes and blood solutions in Fergana ($30 million).
It is expected that production of basic products will be increased threefold in comparison with 2011 year and will exceed 720 million standard units, which will increase the share of domestic products in the total pharmaceutical market to 43 percent from the current 30 percent.
Of the total investment volume in the pharmaceutical industry some $ 145 million will be foreign investment, $ 95 million - loans of Uzbek banks, $50.5 million - local businesses.
Do you have any feedback? Contact our journalist at firstname.lastname@example.org